Expiration date: 05/2025
The composition and form of issue:
Tablets. 1 tablet contains:
active substance:
taurine 250 mg
excipients: MKC — 23 mg potato starch and 18 mg gelatin 6 mg of colloidal silicon dioxide (Aerosil) — 0, 3 mg of calcium stearate — 2, 7 mg
in a contour acheikova packing 10 PCs. in cardboard pack of 3 or 6 packs or in jars of dark glass, of 30 or 60 PCs the paper cartons 1 Bank.
Description pharmaceutical form:
Tablet: white, or almost white color, ploskotsilindricheskie, with riskoj and a facet.
Feature:
Taurine is a natural product of metabolism of sulfur-containing amino acids (cysteine, probably facilitates methionine).
Pharmacokinetics:
After a single dose of 500 mg of Dibicor the active substance (taurine) is determined in the blood after 15-20 min, Cmax achieved after 1, 5-2 hours Fully the drug is excreted through the day.
Description pharmacological action:
Has the and membrane-protective properties, has a positive effect on the phospholipid composition of cell membranes, normalizes the exchange of calcium ions and potassium in the cells. Shows the properties of the inhibitory neurotransmitter, has an antistress effect, can regulate the release of GABA, epinephrine, prolactin (and other hormones) and the response to them.
Dibicor improves metabolic processes in heart, liver and other organs and tissues. In chronic diffuse liver diseases Dibicor increases blood flow and reduces the severity of cytolysis. Treatment with Dibicor heart failure (SSN) leads to a decrease of stagnation in small and big circles of blood circulation: reduces intracardiac diastolic pressure, increased myocardial contractility (maximum rate of contraction and relaxation, the indices of contractility and relaxation). The drug is moderately lowers blood pressure (BP) in patients with arterial hypertension and has virtually no effect on its level in patients with PRS. Dibicor decreases the side effects that occur with an overdose of cardiac glycosides and-blockers slow calcium channels, increases efficiency during extreme physical exertion.
Diabetes approximately 2 weeks after the start of administration of Dibicor decreases the level of blood sugar. It is also noticed a significant decrease in the concentration of triglycerides, to a lesser extent, cholesterol levels, reduction of atherogenic lipids in plasma. Long-term use of the drug (about 6 months) was an improvement of microcirculation of the eye.
Indications:
- cardiovascular failure of various etiologies
- intoxication caused by cardiac glycosides
- diabetes mellitus type 1
- diabetes mellitus type 2, including those with moderate hypercholesterolemia.
Contraindications:
- hypersensitivity to the drug
- the age of 18 years (efficacy and safety not established).
Side effects:
Possible allergic reactions to the drug components.
Drug interactions:
Dibicor can be used with other drugs enhances the inotropic effect of cardiac glycosides.
Method of application and dose:
Inside.
In heart failure Dibicor is the inside of 250-500 mg (1-2 table.) 2 times a day 20 minutes before meals, course of treatment — 30 days. The dose may be increased to 2-3 g (8-12 tables). per day or reduced to 125 mg (1/2 table.) at the reception.
Intoxication cardiac glycosides is not less than 750 mg (3 table.) a day.
Diabetes mellitus type 1, 500 mg (2 table.) 2 times a day in combination with insulin for 3-6 months.
Diabetes type 2 — 500 mg (2 table.) 2 times a day as a monotherapy or in combination with other hypoglycemic agents for oral administration.
Diabetes mellitus type 2, including those with moderate hypercholesterolemia, 500 mg (2 table.) 2 times per day, duration of the course on the advice of the doctor.
Overdose:
There is no information.
Special instructions:
On a background of reception of Dibicor to reduce the dose of cardiac glycosides sometimes 2 times depending on the patients sensitivity to cardiac glycosides. The same rule applies to blockers "slow" calcium channels.
